Baseline characteristics and admission investigations of patients presenting with ST-elevation myocardial infarction comparing the NR group with the control group
| NR | P value | |||
| No (n=149) | Yes (n=24) | |||
| Age (years) | 62±13 | 70±13 | 0.004 | |
| Male | 104 (70) | 14 (58) | 0.3 | |
| History | ||||
| Diabetes mellitus | 21 (14) | 3 (13) | 0.8 | |
| Hypertension | 44 (30) | 12 (50) | 0.047 | |
| Hypercholesterolaemia | 35 (23) | 6 (25) | 0.9 | |
| Ischaemic heart disease | 26 (17) | 4 (17) | 0.9 | |
| Smoking current | 62 (42) | 5 (22) | 0.06 | |
| Ex | 46 (31) | 8 (36) | 0.6 | |
| Examination on admission | ||||
| Weight (kg) | 85±20 | 77±14 | 0.087 | |
| Heart rate (beats/min) | 75±19 | 78±20 | 0.5 | |
| Systolic blood pressure (mm Hg) | 138±28 | 151±30 | 0.03 | |
| Diastolic blood pressure (mm Hg) | 80±16 | 80±18 | 0.9 | |
| Blood glucose | 8.0±3.3 | 8.6±3.6 | 0.4 | |
| Killip class | ||||
| I | 118 (79) | 15 (63) | 0.056 | |
| II | 25 (17) | 7 (29) | ||
| III | 3 (2) | 0 (0) | ||
| IV | 3 (2) | 2 (8) | ||
| Medication use prior to admission | ||||
| Aspirin | 25 (17) | 4 (17) | 1.0 | |
| Dual antiplatelet therapy | 2 (1) | 0 (0) | 0.6 | |
| Anticoagulation warfarin | 7 (5) | 1 (4) | 0.9 | |
| DOAC | 1 (1) | 1 (4) | 0.1 | |
| Statin | 42 (28) | 8 (33) | 0.6 | |
| Time to treatment | ||||
| Symptoms to door time (min) | 511±915 | 681±1185 | 0.4 | |
| Symptoms to balloon time (min) | 543±918 | 720±1195 | 0.4 | |
| Door to balloon time (min) | 32±14 | 39±41 | 0.1 | |
| Symptoms to aspirin time (min) | 435±941 | 628±1268 | 0.4 | |
| Symptoms to P2Y12 antagonist (min) | 510±923 | 656±1205 | 0.5 | |
| Inpatient investigations | Normal range | |||
| Haemoglobin (g/L) | (135–175) | 142±18 | 135±16 | 0.066 |
| Neutrophil (×109/L) | (2.0–7.7) | 11.1±11.5 | 11.5±4.1 | 0.8 |
| Platelet (×109/L) | (150–400) | 248±95 | 216±73 | 0.1 |
| Creatinine (μmol/L) | (50–120) | 79±22 | 91±32 | 0.038 |
| eGFR (mL/min) | (>90) | 89±26 | 78±32 | 0.059 |
| Albumin (g/L) | (35–55) | 36±5 | 34±4 | 0.096 |
| C reactive protein | (<10) | 19±36 | 16±30 | 0.8 |
| NT-proBNP (pg/mL) | (<400) | 1556±2499 | 3305±7708 | 0.047 |
| Resolution of ECG ST change | 88 (64) | 12 (57) | 0.530 | |
| Left ventricular dysfunction | ||||
| None | 62 (43) | 7 (29) | 0.5 | |
| Mild | 46 (32) | 8 (33) | ||
| Moderate | 29 (20) | 6 (25) | ||
| Severe | 9 (6) | 3 (12.5) | ||
Continuous variables are expressed as mean±SD with correlation investigated with one-way analysis of variance. Categorical variables are expressed as number (percentage), with correlation investigated with χ2 test. P<0.05 was deemed significant; however, p<0.1 (bold) suggested further analysis was required.
DOAC, direct-acting oral anticoagulant; eGFR, estimated glomerular filtration rate; NR, no reflow; NT-proBNP, N-terminal pro-B-type natriuretic peptide.